磁靶向利多卡因缓释微球的优化、药代动力学及药效作用半径研究
本研究优化了磁靶向利多卡因微球配方,采用超声乳化-溶剂蒸发法结合Box-Behnken设计,表征微球并测试体外释放;通过非房室模型分析血药浓度,并在兔坐骨神经模型测定药效半径。优化后微球粒径减小、载药量与包封率提高;磁场中t1/2、Tmax、MRT显著延长,AUC0-48与AUC0-∞显著降低,药效半径为31.47 mm。
要点
- 磁靶向利多卡因微球在磁场中半衰期、达峰时间和平均滞留时间显著延长。
- 优化微球粒径减小、载药量和包封率提高,体外释放显示缓释特性。
- 兔坐骨神经模型测得药效半径为31.47 mm,组织安全性高。
核心结论
- 磁靶向利多卡因微球具有缓释、神经靶向、神经阻滞和高组织安全性,可降低局部麻醉药入血。
研究设计与样本
- 采用超声乳化-溶剂蒸发法制备微球,Box-Behnken设计结合响应面法优化,并进行表征和体外释放测试。
- 使用非房室模型分析血药浓度,计算t1/2、最大血药浓度、AUC、Tmax和MRT。
- 通过病理切片评估组织安全性,采用兔坐骨神经模型测定标准时间t0和有效半径。
主要发现
- 优化后微球粒径显著减小,载药量和包封率显著提高。
- 磁场中磁靶向利多卡因微球的t1/2、Tmax和MRT显著延长。
- 磁场中AUC0-48和AUC0-∞显著降低。
- 药效半径为31.47 mm。
关键数值与推荐
- 药效半径为31.47 mm。
- t1/2、Tmax和MRT在磁场中显著延长。
- AUC0-48和AUC0-∞显著降低。
临床怎么用
- 该制剂可能成为改善术后舒适度和治疗慢性疼痛的新方法。
- 为磁载药材料应用时磁场大小的探索提供对策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to optimize the formulation of magnetically targeted lidocaine microspheres, reduce the microsphere particle size, and increase the drug loading and encapsulation rate of lidocaine. The optimized microspheres were characterized, and their pharmacokinetics and effective radii of action were studied. METHODS: The preparation of magnetically targeted lidocaine microspheres was optimized using ultrasonic emulsification-solvent evaporation. The Box-Behnken design method and response surface method were used for optimization. The optimized microspheres were characterized and tested for their in vitro release. Blood concentrations were analyzed using a non-compartment model, and the main pharmacokinetic parameters (half-life (t1/2 ), maximum blood concentration, area under the blood concentration-time curve (AUC), time to peak (Tmax ), and mean retention time (MRT) were calculated. Pathological sections were stained to study the safety of the microsphere tissues. A rabbit sciatic nerve model was used to determine the "standard time (t0 )" and effective radius of the microspheres. RESULTS: The optimized lidocaine microspheres exhibited significantly reduced particle size and increased drug loading and encapsulation rates. Pharmacokinetic experiments showed that the t1/2 , Tmax , and MRT of magnetically targeted lidocaine microspheres were significantly prolonged in the magnetic field, and the AUC0-48 and AUC0-∞ were significantly decreased. Its pharmacodynamic radius was 31.47 mm. CONCLUSION: Magnetically targeted lidocaine microspheres provide sustained long-lasting release, neurotargeting, nerve blocking, and high tissue safety. This preparation has a significantly low blood concentration and a slow release in vivo, which can reduce local anesthetic entry into the blood. This may be a novel and effective method for improving postoperative comfort and treating chronic pain. This provides a countermeasure for exploring the size of the magnetic field for the application of magnetic drug-carrying materials.
引用
- Zheng LX, Yu Q, Peng L, et al. Magnetically targeted lidocaine sustained-release microspheres: optimization, pharmacokinetics, and pharmacodynamic radius of effect. Reg Anesth Pain Med. 2026. PMID: 39223097. doi:10.1136/rapm-2024-105634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。